State Street Corp Acelrx Pharmaceuticals Inc Transaction History

State Street Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$0.2 - $0.35 $1,000 - $1,750	-5,000 Reduced 1.11%	443,731 $93,000
Q1 2022 May 16, 2022	BUY	$0.28 - $0.61 $3,950 - $8,607	14,110 Added 3.25%	448,731 $128,000
Q3 2021 Nov 15, 2021	SELL	$0.93 - $1.51 $17,391 - $28,237	-18,700 Reduced 4.13%	434,621 $443,000
Q2 2021 Aug 16, 2021	SELL	$1.03 - $1.7 $938,019 - $1.55 Million	-910,699 Reduced 66.77%	453,321 $626,000
Q1 2021 May 17, 2021	BUY	$1.25 - $2.77 $93,167 - $206,459	74,534 Added 5.78%	1,364,020 $2.32 Million
Q4 2020 Feb 16, 2021	BUY	$1.18 - $1.98 $246,592 - $413,774	208,977 Added 19.34%	1,289,486 $1.6 Million
Q3 2020 Nov 10, 2020	SELL	$1.01 - $1.81 $11,722 - $21,006	-11,606 Reduced 1.06%	1,080,509 $1.53 Million
Q2 2020 Aug 14, 2020	SELL	$1.03 - $1.69 $338,334 - $555,131	-328,480 Reduced 23.12%	1,092,115 $1.32 Million
Q1 2020 May 11, 2020	BUY	$0.76 - $2.07 $1.08 Million - $2.94 Million	1,420,595 New	1,420,595 $1.68 Million

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.